CoChat

Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer

Gagnon, Jean-François, Bernard, Olivier, Villeneuve, Lyne, Têtu, Bernard, Guillemette, Chantal · 2006 · Clinical Cancer Research

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Purpose: Irinotecan is used in the first-line treatment of metastatic colorectal cancer. The UGT1A1-metabolizing enzyme, expressed in liver and colon, is primarily involved in the inactivation of its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Herein, we explored the role of DNA methylation in the silencing of UGT1A1 gene expression in colon cancer and its influence on cellular SN-38 detoxification. Experimental Design and Results: UGT1A1 mRNA was repressed in most primary tumors (41 of 50; 82%) and in three colon cancer cell lines (HCT-116, HCT-15, and COLO-320DM). Bisulfite sequencing of the UGT1A1 gene revealed the aberrant methylation of specific CpG islands in UGT1A1-negative cells. Conversely, hypomethylation was observed in HT-29, HT-115, and LOVO cells that overexpress UGT1A1. Direct methylation of the UGT1A1 promoter resulted in the complete repression of transcriptional activity. Treatment with demethylating and histone deacetylase inhibitor agents had the capacity to reverse aberrant hypermethylation and to restore UGT1A1 expression in hypermethylated UGT1A1-negative cells but not in hypomethylated cells. Loss of UGT1A1 methylation was further associated with an increase in UGT1A1 protein content and with an enhanced inactivation of SN-38 by 300% in HCT-116 cells. Conclusions: We conclude that DNA methylation represses UGT1A1 expression in colon cancer and that this process may contribute to the level of tumoral inactivation of the anticancer agent SN-38 and potentially influence clinical response.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-2130

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 2

  1. American Cancer Society. Colorectal cancer facts & figures. Special edition 2005. Atlanta: American Cancer Society; 2005.
  2. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998;273:8719–26. · DOI · Paper page

Cited by

See all 118

Metadata

Authors
Gagnon, J.-F., Bernard, O., Villeneuve, L., Têtu, B., & Guillemette, C.
Affiliations
  • Hôtel-Dieu de Québec (CA)
  • 1Canada Research Chair in Pharmacogenomics and
Venue
Clinical Cancer Research
Published
2006-03-15
Volume
12
Issue
6
Pages
1850-1858
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2055695109
Cited by
93
References
50
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 10 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 7
FWCI
1.36
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
irinotecan, UGT1A1, DNA methylation, epigenetic silencing, colon cancer, colorectal cancer, promoter hypermethylation, hypomethylating agents, histone deacetylase inhibitors, drug resistance
MeSH terms
Irinotecan, Decitabine, UGT1A1 Enzyme, Azacitidine, Camptothecin, Humans, Hydroxamic Acids, Glucuronosyltransferase, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, CpG Islands, HT29 Cells, DNA Methylation, Glucuronides, HCT116 Cells, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2130
The paper
Gagnon, J.-F., Bernard, O., Villeneuve, L., Têtu, B., & Guillemette, C. (2006). Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2130

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.